Comparative efficacy of rituximab versus azathioprine in the treatment of MOG antibody-associated disease (MOGAD)

Şen, Sedat; KÜRTÜNCÜ, Murat; Demir, Serkan; GÜNDÜZ, Tuncay; Demirel, Ezgi; Tütüncü, Melih; Uzunköprü, Cihat; Cetinkaya Tezer, Damla; KIZILAY, FERAH; Balcı, Belgin; Arslan, Gökhan; Demir, Caner; Acar Özen, Nazire; Beckmann, Yeşim; Güngör Doğan, İpek; Uygunoğlu, Uğur; Özakbaş, Serkan; Köseoğlu, Mesrure; Gümüş, Haluk; Bilge, Nuray; Aksoy, Dürdane; Kılıç, Ahmet; Yetkin, Mehmet; Akçalı, Aylin; Canbaz Kabay, Sibel; Ethemoğlu, Özlem; Tepe, Nermin; Çilingir, Vedat; Bunul, Sena; Kotan, Dilcan; Gökçe, Şeyda; Bülbül, Nazlı; Akkoyun Arıkan, Fatma; Saip, Sabahattin; Terzi, Murat; Efendi, Hüsnü; Karabudak, Rana; Siva, Aksel; Tuncer, Aslı

doi:10.1016/j.jneuroim.2025.578686

Comparative efficacy of rituximab versus azathioprine in the treatment of MOG antibody-associated disease (MOGAD)

Atıf İçin Kopyala

Şen S., KÜRTÜNCÜ M., Demir S., GÜNDÜZ T., Demirel E., Tütüncü M., ...Daha Fazla

Journal of Neuroimmunology, cilt.407, 2025 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 407
Basım Tarihi: 2025
Doi Numarası: 10.1016/j.jneuroim.2025.578686
Dergi Adı: Journal of Neuroimmunology
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, Chemical Abstracts Core, Psycinfo, Veterinary Science Database
Anahtar Kelimeler: Azathioprine, Disability, MOGAD, Myelin oligodendrocyte glycoprotein associated disease, Rituximab
Van Yüzüncü Yıl Üniversitesi Adresli: Evet

Özet

Background: Azathioprine (AZA) and rituximab (RTX) are frequently used drugs in the treatment of Myelin Oligodendrocyte Glycoprotein Associated Disease (MOGAD). Objectives: The aim of this study was to evaluate the efficacy and safety data of AZA and RTX treatments in MOGAD. Methods: Patients diagnosed according to the 2023 MOGAD diagnostic criteria and receiving AZA or RTX treatment were included in the study. Results: In 142 patients included in the study, the female/male value was 1.2. The rate of OCB positivity in MOGAD patients was 22.6 %. Patients on RTX had higher EDSS values than patients on AZA. However, the RTX group demonstrated a more pronounced improvement in disability, reflected by a greater negative trend in the ΔEDSS values. The attack-free rate was 78 % in the RTX group and 68 % in the AZA group during their treatment period. Both groups had no difference in the time of the first attack. The main factor affecting the time to first attack was having a higher EDSS at the time of treatment initiation. The survival analysis found that EDSS scores improved significantly in patients treated with RTX. Conclusion: Although survival analyses for both treatments appear to be similar, using RTX provides better EDSS scores.